This Medudy course is a video tutorial for physicians on the topic of “New Standards of Care in First-Line Treatment of HER2-Positive Breast Cancer.”
Prof. Dr. Maggie Banys-Paluchowski
, Deputy Director of the Department of Obstetrics and Gynecology
at the University Medical Center Schleswig-Holstein, presents the latest developments in first-line treatment for HER2-positive metastatic breast cancer in this video and then focuses on the DESTINY-Breast09 study.
Despite improvements in adjuvant therapies, there remains an unmet medical need for effective first-line treatment options for HER2-positive breast cancer. Against this backdrop, the interim data from the DESTINY-Breast09 study take on particular significance, as they demonstrate for the first time the superiority of the combination of trastuzumab deruxtecan (T-DXd) and pertuzumab over THP in the first-line setting.
Note: All "speakers" appearing in the Medudy videos are AI-based avatars used to improve the didactics of the videos. The people on whom the avatars are based have explicitly consented to their use. All content is based on high-quality scientific sources and is created and reviewed by the Medudy medical team.
This course was developed with the generous support of Daiichi Sankyo & AstraZeneca.
At the end of this training you will know:
- The development of first-line therapy
- Clinical challenges in HER2-positive breast cancer
- the study design and results of the first interim analysis of DESTINY-Breast09
